Navigation Links
Avastin under trial to test efficacy for pancreatic tumours!

Northwestern Memorial Hospital along with Northwestern University Feinberg School of Medicine is conducting a Phase II clinical trial to determine if avastin is effective in pancreatic tumours.//

The drug also known as bevacizumab is an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumours.

The test is being done to see that it in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumours that have not metastasized or spread to other systems or organs in the body.

Northwestern Memorial is the sole clinical site where the research trial is being conducted.

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti, MD, chief of the Division of Surgical Oncology at Northwestern Memorial Hospital, associate professor of surgery at Northwestern University Feinberg School of Medicine and co-investigator on the study

Another view was presented by William Small, Jr., MD, radiation oncologist, Northwestern Memorial Hospital, associate professor, Radiation Oncology, Northwestern University Feinberg School of Medicine and principal investigator for the trial, "The current study, which will be conducted over two years, will help us evaluate whether adding Avastin may also provide an effective combination to reduce the tumour and increase survival rates. Avastin is designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumour angiogenesis or blood vessel formation, and maintenance of existing tumour vessels. By inhibiting VEGF, Avastin is thought to interfere with the blood supply to tumours, a process that is critical to tumour growth and metastasis.”

As per statistics by the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death among adults in America. Approximately 1 out of 4 patients with pancreatic cancer will live at least one year after the cancer is found.

Therefore it is very important that clinical trials are conducted and new viable solutions are found for this problem.


'"/>




Related medicine news :

1. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
2. Warning on Avastin Updated
3. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
4. Cancer Drug Avastin Fights Brain Tumors too
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. How do babies understand language?
7. Doctor samples come under the ambit of advertisement
8. Latest device for cardiac revival under test
9. Heart disease in women being under-treated
10. Safety of soy under suspicion
11. Education in women brings sounder sleep
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... BC (PRWEB) , ... March 29, 2017 , ... ... makeover services with or without a referral to new patients from Burnaby, BC. ... or other full mouth reconstruction services, can see the esteemed team at ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: